- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06851832
40 세 이상의 건강한 중국 인구에서 재조합 헤르페스 제스터 백신 (Cho Cell)의 임상 시험
40 세 이상의 건강 인구에서 재조합 헤르페스 제스터 백신 (Cho Cell)의 안전성 및 면역 원성을 평가하기위한 무작위, 블라인드, 제어 설계를 갖는 I/II 임상 시험.
The objective of this study was to evaluate the safety, immunogenicity and immune persistence of recombinant herpes zoster vaccine (CHO cells) with different adjuvant doses in healthy people aged 40 years and older.
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 장소
-
-
Henan
-
Xuchang, Henan, 중국
- Xiangcheng County Center for Disease Control and Prevention
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male or female participants aged 40 years or older at the time of enrollment.
- Voluntarily agrees to participate in the trial, fully understands, and signs the informed consent form.
- Able to attend all scheduled follow-ups and comply with the clinical trial protocol requirements to complete the trial.
- Female participants must meet the following criteria:1)Surgically sterilized or postmenopausal for ≥2 years, or women of childbearing potential (not menopausal or menopausal <2 years) with a negative pregnancy test and willing to use effective physical contraception (e.g., condoms, intrauterine device) from enrollment until 6 months after full immunization. 2)Agree not to breastfeed from enrollment until 6 months after full immunization.
- Axillary temperature ≤37.0°C.
Exclusion Criteria:
a Exclusion criteria for the first dose:
- A history of herpes zoster.
- A history of varicella or herpes zoster vaccination.
- Close contact with a varicella/herpes zoster patient within the past year.
- Received immunoglobulin and/or any blood products within 3 months before vaccination.
- Received immunosuppressive treatment within 3 months prior to vaccination (e.g., systemic corticosteroids for ≥14 days, at a dose ≥2 mg/kg/day or ≥20 mg/day of prednisone, or an equivalent dose of prednisone) (excluding inhaled, intra-articular, and topical steroids).
- A history of severe allergic reactions to any vaccine or medication (e.g., anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reactions, severe urticaria, etc.), or a family history of severe allergies.
- Immunocompromised or diagnosed with congenital or acquired immune deficiency diseases, or infected with Human Immunodeficiency Virus (HIV).
- A history of seizures, epilepsy, encephalopathy (such as congenital brain malformation, brain trauma, brain tumors, cerebral hemorrhage, cerebral infarction [except for infarction without sequelae or lacunar infarction], brain infections, or brain damage caused by chemical drug poisoning), or psychiatric disorders, or a family history of psychiatric disorders; or other serious neurological diseases.
- Inadequate time interval between vaccination and other vaccines (e.g., inactivated or recombinant subunit vaccines within 14 days prior to vaccination, live attenuated vaccines, viral vector vaccines, or mRNA vaccines within 28 days prior to vaccination).
- Acute illness or an acute exacerbation of a chronic disease within 3 days prior to vaccination, or use of antipyretic, analgesic, or antihistamine medications within 3 days prior to vaccination.
- Suffering from severe infectious skin diseases.
- Ongoing or long-term alcohol and/or drug abuse history (Note: for the past three months, males drinking more than 14 standard drinks per week, females more than 7 standard drinks per week. One standard drink contains 14g of alcohol, equivalent to 360mL of beer, 45mL of liquor at 40% alcohol, or 150mL of wine. Drug abuse refers to the repeated or excessive use of drugs with dependence potential unrelated to recognized medical needs, for non-medical purposes).
- A history of thrombocytopenia or other coagulation disorders that may contraindicate intramuscular injection.
- Severe liver or kidney disease, complications from diabetes, severe cardiovascular diseases, or uncontrolled hypertension despite medication.
- Asplenia or functional asplenia, or any condition leading to splenectomy.
- Abnormal laboratory test results before the first dose, deemed clinically significant by the investigator (only applicable to Phase I).
- Currently participating in other experimental or unregistered clinical trials for products (drugs, vaccines, or devices), or planning to participate in another clinical trial before the end of this trial.
- A history of hematologic or lymphatic system diseases, such as unexplained lymphadenopathy or hematolymphatic lymphoma.
- A history of diagnosed potential immune-mediated diseases, autoimmune diseases, or Guillain-Barré syndrome.
- Any other condition deemed by the investigator to be unsuitable for participation in this clinical trial.
a Exclusion criteria for the second dose:
- Positive urine pregnancy test.
- Grade 4 adverse events related to vaccination.
- Severe allergic reactions occurring after vaccination.
- New findings or newly occurring conditions that meet the exclusion criteria after the first dose, with the investigator determining whether to terminate the trial vaccine administration.
- Other situations assessed by the investigator as requiring termination of vaccination.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Recombinant zoster Vaccine (CHO cell) (low adjuvant)
It is used for vaccination of experimental vaccine group A subjects in phase I and II clinical trials |
The dosage for each administration is 0.5 mL, containing 50 μg of gE, 0.25 mL of MF59, and 50 μg of CpG1018, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose. |
|
실험적: Recombinant zoster Vaccine (CHO cell)
It is used for vaccination of experimental vaccine group B subjects of phase I clinical trial , experimental vaccine group B1 and B2 subjects of phase II clinical trial |
|
|
활성 비교기: Zoster Vaccine, Live
It is used for vaccination of positive control group A1 and A2 subjects in phase Ⅱ clinical trial |
The dosage for each administration is 0.5 mL, containing not less than 4.3 lg PFU of varicella-zoster live virus, administered subcutaneously at the attachment site of the lower edge of the deltoid muscle on the outer side of the upper arm. A total of one dose will be given. To maintain blinding, the positive control group A1 will receive a placebo on Day 0 and the Zoster Vaccine, Live on Day 30. The positive control group A2 will receive a placebo on Day 0 and the Zoster Vaccine, Live on Day 60. |
|
활성 비교기: Recombinant Zoster Vaccine (CHO cell)
It is used for vaccination of positive control group B subjects in phase Ⅱ clinical trial |
|
|
위약 비교기: Recombinant Zoster Vaccine (CHO cell) (Adjuvant control)
It is used for vaccination of adjuvant control group subjects in phase Ⅰ clinical trial |
The dosage for each administration is 0.5 mL, containing 0.25 mL of MF59 and 100 μg of CpG1018, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose. |
|
위약 비교기: normal saline
Used in phase Ⅰ clinical trial; To maintain blinding, positive control group A1 and positive control group A2 received placebo on day 0 (for phase II clinical trial). |
The dosage for each administration is 0.5 mL, containing 0.5 mL of NaCl solution, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose (applicable to Phase I clinical trial). To maintain blinding, subjects in the positive control A1 and positive control A2 groups will receive a placebo on Day 0 (applicable to Phase II clinical trial). |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
각 백신 복용 후 3 일째에 실험실 이상 (혈액 생화학, 혈액 루틴, 소변 루틴 및 심전도)의 발생률.
기간: 각 백신 용량 후 3 일째.
|
각 백신 용량 후 3 일째.
|
|
|
심각한 부작용 (SAE)의 발생률 및 첫 번째 용량의 백신 접종에서 완전 면역 후 12 개월까지의 특별 관심의 부작용 (AESI).
기간: 첫 번째 용량의 백신 접종에서 완전 면역 후 12 개월까지.
|
첫 번째 용량의 백신 접종에서 완전 면역 후 12 개월까지.
|
|
|
각 백신 용량 후 0-14 일 이내에 요청 된 국소 및 전신 부작용 (AES)의 발생률.
기간: 각 백신 용량 후 14 일 이내에.
|
각 백신 용량 후 14 일 이내에.
|
|
|
각 백신 용량 후 0-30 일 이내에 원치 않는 부작용 (AES)의 발생률.
기간: 각 백신 용량 후 30 일 이내에.
|
각 백신 용량 후 30 일 이내에.
|
|
|
The cell-mediated immune response rate of CD4+ T cells expressing at least two activation markers (IFN-γ, IL-2, TNF-α, CD40L) one month after full immunization.
기간: One month after full immunization.(Applicable to Phase Ⅱ only)
|
Detected using intracellular cytokine staining (ICS) by flow cytometry |
One month after full immunization.(Applicable to Phase Ⅱ only)
|
|
The GMC/GMT, seroconversion rate, and GMI of anti-gE antibodies and anti-VZV antibodies one month after full immunization.
기간: One month after full immunization.(Applicable to Phase Ⅱ only)
|
Detected using enzyme-linked immunosorbent assay (ELISA). |
One month after full immunization.(Applicable to Phase Ⅱ only)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
The GMC/GMT, seroconversion rate, and GMI of anti-gE antibodies and anti-VZV antibodies at 6, 12, 24, and 36 months after full immunization.
기간: At 6, 12, 24, and 36 months after full immunization.(Applicable to Phase Ⅱ only)
|
Detected using enzyme-linked immunosorbent assay (ELISA) |
At 6, 12, 24, and 36 months after full immunization.(Applicable to Phase Ⅱ only)
|
|
The cell-mediated immune response rate of CD4+ T cells expressing at least two activation markers (IFN-γ, IL-2, TNF-α, CD40L) before the second dose and at 6, 12, 24, and 36 months after full immunization.
기간: Before the second dose and at 6, 12, 24, and 36 months after full immunization(Applicable to Phase Ⅱ only)
|
Detected using intracellular cytokine staining (ICS) by flow cytometry |
Before the second dose and at 6, 12, 24, and 36 months after full immunization(Applicable to Phase Ⅱ only)
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Zhiqiang Xie, Master, Henan Center for Disease Control and Prevention
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- VZV-ZHSW-01
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .